You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森制药(03692.HK)与EQRX订立许可协议
格隆汇 07-23 08:15

格隆汇 7 月 23日丨翰森制药(03692.HK)发布公告,2020年7月22日(交易时段前),翰森(上海)健康科技有限公司和江苏豪森药业集团有限公司(统称“许可人”,均为集团的全资附属公司)与EQRx,INC.订立战略合作及许可协议,据此许可人授予EQRx(其中包括)排他性许可,容许其在中国境外及在癌症、与癌症相关和免疫炎症性疾病的治疗领域内研究、开发、生产和商业化阿美替尼(及任何包含或由阿美替尼组成的产品)。阿美替尼是公司其中一项核心产品,并已在中国获药品注册批件,用于既往经EGFR-TKI治疗进展,且T790M突变阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。

根据许可协议并按照其中的条款及条件,许可人有权收取首付款和注册与发展里程碑付款,金额约1亿美元(不包括其他潜在的商业里程碑付款和基于净销售额的分层特许权使用费)。该里程碑付款须达成相关里程碑事件时方可作实,并于首次发生相关里程碑事件时予以支付。根据许可协议,EQRx须遵守惯常的排他性不竞争义务,而许可人和EQRx须遵守惯常的相互陈述、保证、契约和弥偿保证。

EQRx是一家总部位于美国的生物制药公司,专注于以大众化价格生产创新药物,为社会带来可持续发展。EQRx主要从事发掘、开发和商业化创新药物的业务。

凭藉EQRx卓越的领导团队,及在肿瘤治疗领域的临床开发方面具有的丰富经验,公司预期EQRx将能有利于加快阿美替尼在中国境外的临床开发。倘获准推出市场,将能使阿美替尼造福于全球更多有需要的癌症患者,而集团与EQRx的深入合作将进一步提升公司在临床试验开发及产品商业化方面的经验及基础。因此董事会相信,许可协议及据此拟进行的交易符合公司及其股东的整体利益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account